- Comment
- Published:
An analysis of Investigational New Drug (IND) submissions to the US Food and Drug Administration (FDA) from 1995 to 2025 reveals a rapid growth in adeno-associated virus (AAV) development over three decades and highlights common reasons for regulatory holds that should be considered for successful product development.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$39.99 / 30 days cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
-
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Signal Transduct. Target. Ther. 6, 53 (2021).
-
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L. & Gao, G. Signal Transduct. Target. Ther. 9, 78 (2024).
-
Li, C. & Samulski, R. J. Nat. Rev. Genet. 21, 255–272 (2020).
-
Duan, D. et al. J. Virol. 72, 8568–8577 (1998).
-
Dong, B., Nakai, H. & Xiao, W. Mol. Ther. 18, 87–92 (2010).
-
Gao, G. et al. J. Virol. 78, 6381–6388 (2004).
-
Maguire, A. M. et al. N. Engl. J. Med. 358, 2240–2248 (2008).
-
Lapteva, L., Purohit-Sheth, T., Serabian, M. & Puri, R. K. Mol. Ther. Methods Clin. Dev. 19, 387–397 (2020).
-
Nathwani, A. C. et al. N. Engl. J. Med. 371, 1994–2004 (2014).
-
Mingozzi, F. & High, K. A. Blood 122, 23–36 (2013).
-
Russell, S. et al. Lancet 390, 849–860 (2017).
-
Foust, K. D. et al. Nat. Biotechnol. 27, 59–65 (2009).
-
Pacak, C. A. et al. Circ. Res. 99, e3–9 (2006).
-
Srivastava, A. Curr. Opin. Virol. 21, 75–80 (2016).
-
Wang, L. et al. Mol. Ther. 18, 118–125 (2010).
-
Grimm, D. et al. J. Virol. 82, 5887–5911 (2008).
-
Hinderer, C. et al. Hum. Gene Ther. 29, 285–298 (2018).
-
Laforet, G. A. Hum. Gene Ther. 36, 64–76 (2025).
Acknowledgements
We thank Z. Ye, K. Schultz, S. Butler, A. Harmon, R. Vatsan, D. Gavin, A. Harvan and P. Kurs for valuable review, feedback and advice. The opinions presented in this article are those of the authors and do not necessarily represent the views or policies of FDA. This article does not include all programs, policies and incentives available for development of novel therapies for rare diseases.
Ethics declarations
Competing interests
All authors are employed by the US Food and Drug Administration.
Supplementary information
Rights and permissions
About this article
Cite this article
Bing, S., Argaw, T., Kaushal, M. et al. A comprehensive analysis of CBER experience with AAV gene therapy IND submissions. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03378-9
-
Published:
-
Version of record:
-
DOI: https://doi.org/10.1038/s41587-026-03378-9